DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Provided By PR Newswire
Last update: Jan 28, 2025
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial
Read more at prnewswire.com
